ES2483726T3 - Inhibidores de la P70 S6 quinasa - Google Patents

Inhibidores de la P70 S6 quinasa Download PDF

Info

Publication number
ES2483726T3
ES2483726T3 ES08747285.8T ES08747285T ES2483726T3 ES 2483726 T3 ES2483726 T3 ES 2483726T3 ES 08747285 T ES08747285 T ES 08747285T ES 2483726 T3 ES2483726 T3 ES 2483726T3
Authority
ES
Spain
Prior art keywords
phenyl
imidazol
trifluoromethyl
piperidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08747285.8T
Other languages
English (en)
Spanish (es)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L. Holst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2483726T3 publication Critical patent/ES2483726T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES08747285.8T 2007-05-11 2008-05-01 Inhibidores de la P70 S6 quinasa Active ES2483726T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
US917331P 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2483726T3 true ES2483726T3 (es) 2014-08-07

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08747285.8T Active ES2483726T3 (es) 2007-05-11 2008-05-01 Inhibidores de la P70 S6 quinasa

Country Status (33)

Country Link
US (2) US8093383B2 (Direct)
EP (1) EP2148880B1 (Direct)
JP (1) JP5503532B2 (Direct)
KR (1) KR101088219B1 (Direct)
CN (1) CN101679439B (Direct)
AR (1) AR066344A1 (Direct)
AU (1) AU2008251692B2 (Direct)
BR (1) BRPI0811212A2 (Direct)
CA (1) CA2687265C (Direct)
CL (1) CL2008001230A1 (Direct)
CO (1) CO6241109A2 (Direct)
CR (1) CR11106A (Direct)
DK (1) DK2148880T3 (Direct)
DO (1) DOP2009000257A (Direct)
EA (1) EA016445B1 (Direct)
EC (1) ECSP099721A (Direct)
ES (1) ES2483726T3 (Direct)
GT (1) GT200900292A (Direct)
HR (1) HRP20140611T1 (Direct)
IL (1) IL201564A (Direct)
MA (1) MA31433B1 (Direct)
MX (1) MX2009012075A (Direct)
MY (1) MY154898A (Direct)
NZ (1) NZ580423A (Direct)
PE (1) PE20090887A1 (Direct)
PL (1) PL2148880T3 (Direct)
PT (1) PT2148880E (Direct)
RS (1) RS53451B (Direct)
SI (1) SI2148880T1 (Direct)
TN (1) TN2009000446A1 (Direct)
TW (1) TWI423805B (Direct)
UA (1) UA99284C2 (Direct)
WO (1) WO2008140947A1 (Direct)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
EP2355821A1 (en) * 2008-11-11 2011-08-17 Eli Lilly and Company P70 s6 kinase inhibitor and egfr inhibitor combination therapy
EA018824B1 (ru) * 2008-11-11 2013-10-30 Эли Лилли Энд Компани КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРОМ КИНАЗЫ p70 S6 И ИНГИБИТОРОМ mTOR
JP5642714B2 (ja) 2009-02-11 2014-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 新規なアミノアザヘテロ環式カルボキサミド
BR112012002336A2 (pt) 2009-08-07 2016-05-31 Merck Patent Gmbh compostos aza-heterocíclicos
MX2012004780A (es) * 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
JP6114554B2 (ja) 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ,エルエルシー Torキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのlkb1変異の同定
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
SI2643313T1 (sl) 2010-11-24 2016-11-30 Merck Patent Gmbh Kinazolin-karboksamidni azetidini
WO2013040044A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
WO2013040059A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドPlexxikon Inc. キナーゼをモジュレートするための化合物および方法、ならびにその指標
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
WO2014078634A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
WO2014143612A1 (en) * 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー 癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
SG11201508223YA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2015149909A1 (en) 2014-04-03 2015-10-08 Merck Patent Gmbh Combinations of cancer therapeutics
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ,エルエルシー 1−エチル−7−(2−メチル−6−(1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン及び共形成物を含む固体形態、その組成物及び使用方法
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
KR20230110296A (ko) 2020-11-16 2023-07-21 메르크 파텐트 게엠베하 암 치료를 위한 키나제 억제제 조합

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
EP2148880B1 (en) 2014-05-28
CL2008001230A1 (es) 2009-05-22
PE20090887A1 (es) 2009-07-13
WO2008140947A1 (en) 2008-11-20
RS53451B (sr) 2014-12-31
CN101679439A (zh) 2010-03-24
TN2009000446A1 (en) 2011-03-31
AU2008251692B2 (en) 2012-10-11
US8093383B2 (en) 2012-01-10
ECSP099721A (es) 2009-12-28
IL201564A (en) 2014-08-31
MX2009012075A (es) 2009-11-19
CR11106A (es) 2010-04-12
CA2687265C (en) 2012-12-04
KR20100005710A (ko) 2010-01-15
MY154898A (en) 2015-08-28
JP5503532B2 (ja) 2014-05-28
US20090163714A1 (en) 2009-06-25
CA2687265A1 (en) 2008-11-20
MA31433B1 (fr) 2010-06-01
AU2008251692A1 (en) 2008-11-20
AR066344A1 (es) 2009-08-12
KR101088219B1 (ko) 2011-11-30
EP2148880A1 (en) 2010-02-03
PL2148880T3 (pl) 2014-10-31
HRP20140611T1 (hr) 2014-08-15
UA99284C2 (ru) 2012-08-10
US20120071490A1 (en) 2012-03-22
JP2010526814A (ja) 2010-08-05
GT200900292A (es) 2011-06-24
NZ580423A (en) 2012-02-24
IL201564A0 (en) 2010-05-31
DOP2009000257A (es) 2010-03-31
CO6241109A2 (es) 2011-01-20
CN101679439B (zh) 2013-09-11
HK1140767A1 (en) 2010-10-22
PT2148880E (pt) 2014-08-28
TWI423805B (zh) 2014-01-21
DK2148880T3 (da) 2014-06-16
EA016445B1 (ru) 2012-05-30
TW200848053A (en) 2008-12-16
SI2148880T1 (sl) 2014-07-31
EA200971051A1 (ru) 2010-06-30
BRPI0811212A2 (pt) 2014-10-29

Similar Documents

Publication Publication Date Title
ES2483726T3 (es) Inhibidores de la P70 S6 quinasa
ES2796377T3 (es) Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
ES2947411T3 (es) Sales cristalinas de un campo inhibidor de quinasa B-RAF
ES2391704T3 (es) Inhibidores de cinasa AKT y P70 S6
EP2943485B1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
CN121399123A (zh) 作为突变型kras g12c抑制剂用于治疗癌症的吡啶并[4,3-d]嘧啶衍生物
WO2019170543A1 (en) Identification and use of erk5 inhibitors
CN121419980A (zh) 作为突变型kras g12c抑制剂用于治疗癌症的吡啶并[4,3-d]嘧啶衍生物
JP2024502258A (ja) Cgasに関連する状態の処置に有用なインドール誘導体
CA3122136A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
CA3022758C (en) Treatment of skin lesions
EP4069369A1 (en) Cyclic compounds and methods of using same
JP7808616B2 (ja) 環式化合物及びそれを使用する方法
HK1140767B (en) P70 s6 kinase inhibitors
KR20250078953A (ko) 사이클린-의존성 키나아제 7 억제제
WO2025160079A1 (en) Indazolo-amino-pyrimidinone compounds
CN120004864A (zh) 双环化合物,包含其的组合物及其应用
CN116490507A (zh) 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
HK40098127A (en) Crystalline salts of a b-raf kinase inhibitor